SEQENS Announces New CEO Pascal Villemagne Effective 2025
Portfolio - People | Feb 19, 2025 | SK Capital
SEQENS, a leading provider of active pharmaceutical ingredients and specialty ingredients headquartered in France, has announced the appointment of Pascal Villemagne as the new Chief Executive Officer effective April 1, 2025. Pascal brings extensive experience from previous roles, including senior positions at CARBOGEN AMCIS, Farmhispania, Inabata, Cambrex, and Sanofi, which has equipped him with the requisite industry insights and leadership acumen for his new role. His appointment is expected to strengthen SEQENS' strategic direction in the pharmaceutical services industry, especially given the ongoing technological investments facilitated by SK Capital, the private equity owner. The outgoing CEO, Pierre Luzeau, who has led SEQENS since 2006, will transition into the role of Independent Director and Chairman of the CSR Committee on the Supervisory Board, ensuring continuity in leadership as SEQENS embarks on its next growth phase following the acquisition of CellforCure in 2023.
Sectors
- Pharmaceuticals
- Private Equity
Geography
- France – SEQENS is headquartered in France and is a significant player in the French pharmaceutical sector.
Industry
- Pharmaceuticals – SEQENS operates within the pharmaceuticals industry, focusing on the development and production of active pharmaceutical ingredients and pharmaceutical intermediates.
- Private Equity – SK Capital is a private equity firm involved in the ownership and strategic direction of SEQENS.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SEQENS | Company | Target company | SEQENS is a French company specializing in the development and production of pharmaceutical and specialty ingredients. |
| SK Capital | Private Equity Firm | Bidding Company | SK Capital is a private equity firm that owns SEQENS and is involved in strategic decisions regarding the company. |
| Pascal Villemagne | Incoming CEO | Person | Pascal Villemagne has been appointed as the new CEO of SEQENS and brings significant experience from various leadership roles in the pharmaceutical industry. |
| Pierre Luzeau | Outgoing CEO & Future Board Member | Person | Pierre Luzeau has been CEO of SEQENS since 2006 and will transition to be an Independent Director and Chairman of the CSR Committee. |
| Aaron Davenport | Managing Director | Person | Aaron Davenport is a Managing Director at SK Capital and plays a key role in the strategic direction of SEQENS. |